Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
Hematology Disease Topics & Pathways:
Research, AML, Acute Myeloid Malignancies, Translational Research, drug development, Diseases, Therapies, Myeloid Malignancies
Compared with OST-01 alone or V, combination of OST-01 and the BCL-2 inhibitor, venetoclax (VEN) demonstrated a synergistic activity on AML cell lines and primary blasts (max synergy score: 28.16), and prolonged survival of MllPTD/WT/Flt3ITD/ITD AML mice (VEN/OST vs OST and VEN, median: 156 vs 123 and 95 days, p=0.0003 and p<0.0001; secondary transplant median: 105 vs 58 and 31 days, p<0.0001 and p<0.0001, respectively) and CM AML mice (VEN/OST vs OST and VEN, median: 85 vs 70 and 58 days, p=0.0005 and p<0.0001; secondary transplant median: 95 vs 62.5 and 48 days, p=0.0003 and p<0.0001, respectively).
To gain insights into the mechanism of action of OST-01, we performed RNA-seq on OST-01- or V-treated HL-60 cells and CD34+CD38- AML blasts. By GSEA analysis, we identified 50 enriched Hallmark gene sets (26 upregulated and 24 downregulated) in OST-01- vs V-treated HL-60 cells and 49 (32 upregulated and 17 downregulated) in OST-01- vs V-treated CD34+CD38- AML blasts. The Hallmark gene sets comprising Myc targets were among the most downregulated in OST-01-treated cells. We confirmed these results showing an OST-01-dependent decrease in c-myc, inhibition of c-myc signaling, and deregulation of c-myc-dependent nucleolar structure and ribosome biogenesis in HL-60 cells and CD34+CD38- AML blasts. To this end, OST-01 enhanced ubiquitination and degradation of c-myc and nucleolar proteins (NPM1, NS, nucleolin) and in turn induced nucleolar disruption as shown by immunoblotting, immunoprecipitation, and electron microscope imaging in HL-60 cells and CD34+CD38- AML blasts. Of note, OST-01 also inhibited ErbB3 binding protein 1 (Ebp1)-enhanced ribosomal RNA (rRNA) synthesis through upregulation of expression and function of RNA Polymerase I (Pol I) and DEAD-box helicase 21 (DDX21).
In summary, we provide the first report of a significant in vivo antileukemic activity of a novel NP, OST-01. The mechanisms of action of OST-01 are mediated by inhibition of c-myc-dependent signaling, rRNA synthesis and ribosome biogenesis. To date, no preclinical toxicity has been observed. We concluded that OST-01 is a non-toxic, potentially new therapy for AML; translation from the bench to the bedside is underway.
Disclosures: Graff: Ostentus Therapeutics: Current equity holder in private company. Nguyen: Ostentus Therapeutics: Current equity holder in private company. Marcucci: Ostentus Therapeutics: Current equity holder in private company, Research Funding.